ICON plc (ICLR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- CRO Clinical Researchsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.68% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Icon's 2027 Outlook Supported by Strong Bookings as Growth Questions Persist, RBC Says
- ICON Schedules Third Quarter 2026 Earnings Conference Call
- Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
- ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen
- ICON Public Limited Company (ICLR) Surges on Net Book-to-Bill Strength
- ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability
- ICON Announces Pricing of USD 2.15 Billion Notes
- ICON Announces Private Offering of Notes
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ICON plc.
Full ICLR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.